List view / Grid view
A DNDi-commissioned report on the Malaysian reaction to COVID-19 has revealed the strengths and weaknesses of the country’s response.
The UK government reserved a production line at Wockhardt for 18 months to ensure the rapid fill finish of COVID-19 vaccines.
An initial 450,000 of Oxford Nanopore's LamPORE test will be used by the UK government as COVID-19 diagnostics, which yield results in under two hours.
Sanofi and GSK have reached an agreement with the UK government to supply up to 60 million doses of their COVID-19 vaccine.
According to a new report from the International Trade Committee, the UK's medicine supply chain was able to withstand the challenge of COVID-19, but must be optimised for a potential second wave of the virus.
The UKRI and NIHR will fund projects worth £4.3 million to investigate the disproportionate death rate from COVID-19 among people from BAME backgrounds.
The CEO of PQE Group has formed a task force of employees in the corporate community to research and dispel fake news regarding COVID-19.
The EMA has begun to review dexamethasone to provide an opinion on the results of the RECOVERY study for the treatment of adults admitted to hospital with COVID-19.
The BNT162b2 mRNA-based vaccine produced by Pfizer and BioNTech will enter Phase have II/III clinical trials to test its safety and efficacy against COVID-19.
The UK government has committed £100 million to establish a centre to scale up COVID-19 vaccine and gene therapy manufacturing.
Novavax and FUJIFILM Diosynth Biotechnologies have agreed for FDB to make the bulk drug substance for NVX-CoV2373, the Novavax COVID-19 vaccine candidate.
An agreement between the US government and Pfizer and BioNTech will have the companies produce an initial 100 million doses of their COVID-19 vaccine candidate, with the potential for 500 million more.
Does expert knowledge on COVID-19 need to be more accessible across the globe? This article explores this issue and addresses how greater accessibility could help fight the pandemic in emerging countries.
The vaccine containing a recombinant coronavirus virus-like particles (CoVLP) will be tested in three different doses and with two different adjuvants.
Data released from the Phase I/II trial of the ChAdOx1 COVID-19 vaccine candidate suggests it elicits an immune response with no adverse effects.
